<DOC>
	<DOCNO>NCT01792804</DOCNO>
	<brief_summary>Increasing resistance antibiotic agent recognize major health problem worldwide even aggravate due lack new antimicrobial agent within next decade [ 1 ] . This threat underscore need maximize clinical utility exist antibiotic , rational prescription , e.g . optimize duration treatment . Staphylococcus aureus bloodstream infection ( SAB ) common disease 200,000 case occur annually Europe [ 2 ] . A course least 14 day intravenous antimicrobial consider standard therapy [ 3-5 ] `` uncomplicated '' SAB . This relatively long course serf prevent SAB-related complication ( endocarditis vertebral osteomyelitis ) may result hematogenous dissemination distant site . However , insufficient evidence full course intravenous antibiotic therapy always require patient low risk SAB-related complication . In multicenter , open-label , randomize control trial aim demonstrate early switch intravenous oral antimicrobial therapy non-inferior conventional 14-days course intravenous therapy regard efficacy safety . An early switch intravenous oral therapy would provide several benefit earlier discharge , few adverse reaction associate intravenous therapy , increase quality life , cost saving .</brief_summary>
	<brief_title>Staphylococcus Aureus Bacteremia Antibiotic Treatment Options</brief_title>
	<detailed_description>1. WHO . WHO Global Strategy Containment Antimicrobial Resistance . : World Health Organization , 2001 . 2 . Kern WV . Management Staphylococcus aureus bacteremia endocarditis : progress challenge . Curr Opin Infect Dis 2010 ; 23 ( 4 ) :346-58 . 3 . Gemmell CG , Edwards DI , Fraise AP , Gould FK , Ridgway GL , Warren RE . Guidelines prophylaxis treatment methicillin-resistant Staphylococcus aureus ( MRSA ) infection UK . J Antimicrob Chemother 2006 ; 57 ( 4 ) :589-608 . 4 . Liu C , Bayer A , Cosgrove SE , et al . Clinical practice guideline Infectious Diseases Society America treatment methicillin-resistant Staphylococcus aureus infection adult child . Clin Infect Dis 2011 ; 52 ( 3 ) : e18-55 . 5 . Mermel LA , Allon M , Bouza E , et al . Clinical practice guideline diagnosis management intravascular catheter-related infection : 2009 Update Infectious Diseases Society America . Clin Infect Dis 2009 ; 49 ( 1 ) :1-45 .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Staphylococcal Infections</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Clindamycin</mesh_term>
	<mesh_term>Clindamycin palmitate</mesh_term>
	<mesh_term>Clindamycin phosphate</mesh_term>
	<mesh_term>Daptomycin</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<mesh_term>Cefazolin</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<mesh_term>Trimethoprim , Sulfamethoxazole Drug Combination</mesh_term>
	<mesh_term>Cloxacillin</mesh_term>
	<mesh_term>Floxacillin</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<criteria>Age least 18 year Not legally incapacitate Written informed consent trial subject obtain Blood culture positive S. aureus consider represent contamination At least one negative followup blood culture obtain within 2496 hour start adequate antimicrobial therapy rule persistent bacteremia Absence blood culture positive S. aureus time thereafter . Five seven full day appropriate i.v . antimicrobial therapy administer prior randomization document patient Chart . Appropriate therapy follow characteristic : 1 . Antimicrobial therapy initiate within 72h first positive blood culture drawn . 2 . Provided invitro susceptibility adequate dosing ( judged PI ) prefer agent prerandomization antimicrobial therapy flucloxacillin , cloxacillin , vancomycin daptomycin . However , follow antimicrobial allow : MSSR : penicillinaseresistant penicillin ( e.g . flucloxacillin , cloxacillin ) , βlactam plus βlactamaseinhibitors ( e.g . ampicillin+sulbactam , piperacillin+tazobactam ) , cephalosporin ( except ceftazidime ) , carbapenems , clindamycin , fluoroquinolones , trimethoprimsulfamethoxazole , doxycycline , tigecycline , vancomycin , teicoplanin , telavancin , linezolid , daptomycin , ceftaroline , ceftobiprole , macrolides . MRSA : vancomycin , teicoplanin , telavancin , fluoroquinolones , clindamycin , trimethoprimsulfamethoxazole , doxycycline , tigecycline , linezolid , daptomycin , macrolides , ceftaroline , ceftobiprole . Polymicrobial bloodstream infection , define isolation pathogen S. aureus blood culture obtain time two day prior first positive blood culture S. aureus randomization . Common skin contaminant ( coagulasenegative staphylococci , diphtheroids , Bacillus spp. , Propionibacterium spp . ) detect one several blood culture consider represent polymicrobial infection Recent history ( within 3 month ) prior S. aureus bloodstream infection In vitro resistance S. aureus oral i.v . study drug Contraindications oral i.v . study drug Previously plan Treatment active drug S. aureus Intervention Phase ( e.g . cotrimoxazol prophylaxis ) Signs symptom complicate SAB judge ID physician . Complicated infection define least one follwoing : deepseated focus : e.g . endocarditis , pneumonia , undrained abscess , empyema , Osteomyelitis septic shock , define AACP criterion ( 23 ) , within 4 day randomization prolong bacteremia : positive followup blood culture 72h start adequate antimicrobial therapy body temperature &gt; 38 °C two separate day within 48h randomization Presence follow nonremovable foreign body ( remove 2 day randomization ) : prosthetic heart valve deepseated vascular graft foreign material ( e.g . PTFE dacron graft ) . Hemodialysis shunt consider deepseated vascular graft . ventriculoatrial shunt Presence prosthetic joint ( remove 2 day randomization ) . This exclusion criterion , follow condition fulfil : prosthetic joint implant least 6 month prior , catheterrelated infection , skin soft tissue infection , surgical wound infection present ( define ) , joint infection unlikely ( clinical imaging sign ) Presence pacemaker automate implantable cardioverter Defibrillator ( AICD ) device ( remove 2 day randomization ) . This exclusion criterion , follow condition fulfil : pacemaker AICD implant least 6 month prior , catheterrelated infection , skin soft tissue infection , surgical wound infection present ( define ) , clinical sign infective endocarditis , infective endocarditis unlikely echocardiography ( preferably TEE ) , pocket infection unlikely ( clinical imaging sign ) Failure remove intravascular catheter present first positive blood culture drawn within 4 day first positive blood culture Severe liver disease . This exclusion criterion , follow condition fulfil : catheterrelated infection , skin soft tissue infection , surgical wound infection present Endstage renal disease . This exclusion criterion , follow condition fulfil : catheterrelated infection , skin soft tissue infection , surgical wound infection present ( define ) , clinical sign infective endocarditis , infective endocarditis unlikely echocardiography ( preferably TEE ) , patient hemodialysis shunt nonremovable foreign body ( e.g . synthetic PTFE loop ) : clinical sign shunt infection Severe immunodeficiency primary immunodeficiency disorder neutropenia ( &lt; 500 neutrophils/μl ) randomization neutropenia expect intervention phase due immunosuppressive treatment uncontrolled disease HIVpositive patient highdose steroid therapy ( &gt; 1 mg/kg prednisone equivalent dos give &gt; 4 week plan intervention ) immunosuppressive combination therapy two drug different mode action hematopoietic stem cell transplantation within past 6 month plan treatment period solid organ transplant treatment biologicals within previous year Life expectancy &lt; 3 month Inability take oral drug Injection drug user Expected low compliance drug regimen Participation interventional trial within previous three month ongoing Pregnant woman nurse mother For premenopausal woman : Failure use highlyeffective contraceptive method 1 month receive study drug . The following contraceptive method Pearl Index lower 1 % regarded highlyeffective : oral hormonal contraception ( 'pill ' ) dermal hormonal contraception vaginal hormonal contraception ( NuvaRing® ) contraceptive plaster longacting injectable contraceptive implant release progesterone ( Implanon® ) tubal ligation ( female sterilisation ) intrauterine device release hormone ( hormone spiral ) double barrier method Persons kind dependency investigator employ sponsor investigator Persons hold institution legal official order</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Staphylococcus aureus</keyword>
	<keyword>Bloodstream infection</keyword>
	<keyword>Oral switch</keyword>
</DOC>